Titlebook: Soft Tissue Sarcomas; Laurence H. Baker Book 1983 Martinus Nijhoff Publishers, Boston 1983 Staging.cancer treatment.pathology.radiotherapy

尖

Changing Concepts in Pathology,of the histogenetic concept of a group of sarcomas, the malignant fibrous histiocytomas (MFH), has resulted in an extension of the classification and a decrease in the diagnosis of pleomorphic liposarcomas, pleomorphic rhabdomyosarcomas, and unclassifiable or undifferentiated sarcomas. Though the ce

現(xiàn)暈光

方便

排名真古怪

斑駁

ALIAS

Perfusion Chemotherapy,h very few local or systemic symptoms and often are misdiagnosed and treated as ’chronic hematomas’ or muscle group ruptures for a long period of time. Furthermore, there is confusion in pathologic nomenclature of these tumors and the biologic importance of the various histogenic varieties. The orig

subacute

Aids209

Role of Radiotherapy,adical surgical excision has been considered the only curative treatment since soft tissue sarcomas were known to be ‘radioresistant.’ This concept of radioresistance was based on early published reports. In 1928, Rostock [1] reported on a collected series of 505 patients with soft tissue sarcoma. A

resilience

Chemotherapy of Disseminated Soft Tissue Sarcomas,ted sarcomas. Previously, there were scattered reports in the literature indicating that different sarcomas were responsive to chemotherapeutic drugs, principally cyclophosphamide, actinomycin, and vincristine. Relatively few of these series had sufficient numbers of patients treated in a similar th

Aerate

Phase II New Drug Trials in Soft Tissue Sarcomas, sarcomas. The response rate to doxorubicin varies from 13–34% [1–4]. Several clinical trials have established that a dose-response relationship exists and may account for the variable response data observed [5–8]. Studies employing various combinations of doxorubicin including doxorubicin-DTIC, dox